Curtis Jamison Perry, MD, PhD
Instructor of Medicine (Medical Oncology & Hematology)About
Research
Publications
2025
Transcriptomic landscape of Kaposi sarcoma: Insights into therapeutic targeting of KSHV.
Fei Y, Costa P, Junejo M, Li M, Perry C, Damsky W, Ishizuka J. Transcriptomic landscape of Kaposi sarcoma: Insights into therapeutic targeting of KSHV. Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.e23526.Peer-Reviewed Original ResearchKaposi's sarcoma herpesvirusKaposi's sarcomaTranscripts Per MillionKSHV genomeHIV statusPresence of Kaposi’s sarcoma herpesvirusDisease progressionLatency-associated regionExpressed genesHistory of organ transplantationVirus-associated tumorsTherapeutic targetFormalin-fixed paraffin-embedded (FFPEGene expressionParaffin-embedded (FFPEHuman herpesvirus 8Differential gene expression analysisDisseminated diseaseViral eradicationViral gene expressionHIV-positiveBaseline characteristicsHHV-8Gene expression analysisTumor morphologyPerturbational single-cell RNA sequencing of patient tumors in Merkel cell and small cell lung carcinomas.
Perry C, Frey A, Fei Y, Costa P, Wang J, Ghadermarzi S, Levine D, Koda A, Nassar A, Ding M, Nie Y, Cordero-Dumit T, Augert A, van Djik D, Olino K, Ishizuka J. Perturbational single-cell RNA sequencing of patient tumors in Merkel cell and small cell lung carcinomas. Journal Of Clinical Oncology 2025, 43: 2520-2520. DOI: 10.1200/jco.2025.43.16_suppl.2520.Peer-Reviewed Original ResearchSmall cell lung cancerMerkel cell carcinomaMonocyte-derived DCCD14+ monocytesT cellsPatient tumorsResponse to IFNImpact of immune checkpoint blockadeTumor-infiltrating T cellsCo-CultureSmall cell lung carcinomaTumor immunity cycleImmune checkpoint blockadeImmune cells co-culturedCell lung carcinomaInnate immune signaturesHuman tumor specimensCell lung cancerLymph node metastasisCell linesFactors associated with responseLong-term survivalAssociated with nonresponseStandard of careImmune samples
2023
Clinical Predictors of Survival in Patients With BRAFV600-Mutated Metastatic Melanoma Treated With Combined BRAF and MEK Inhibitors After Immune Checkpoint Inhibitors
Kahn A, Perry C, Etts K, Kluger H, Sznol M. Clinical Predictors of Survival in Patients With BRAFV600-Mutated Metastatic Melanoma Treated With Combined BRAF and MEK Inhibitors After Immune Checkpoint Inhibitors. The Oncologist 2023, 29: e507-e513. PMID: 37971411, PMCID: PMC10994263, DOI: 10.1093/oncolo/oyad300.Peer-Reviewed Original ResearchBRAF/MEK inhibitorsBRAF/MEK inhibitionImmune checkpoint inhibitorsBRAFV600E/K mutationsMEK inhibitorsCheckpoint inhibitorsClinical variablesMEK inhibitionRetrospective single-institution analysisIpilimumab/nivolumabFirst-line settingFirst-line therapyFirst-line treatmentMetastatic melanoma patientsLong-term outcomesPretreatment clinical variablesSingle-institution analysisStratification of patientsK mutationCombined BRAFECOG PSMedian OSRECIST 1.1Immunotherapy regimenClinical characteristicsCausal identification of single-cell experimental perturbation effects with CINEMA-OT
Dong M, Wang B, Wei J, de O. Fonseca A, Perry C, Frey A, Ouerghi F, Foxman E, Ishizuka J, Dhodapkar R, van Dijk D. Causal identification of single-cell experimental perturbation effects with CINEMA-OT. Nature Methods 2023, 20: 1769-1779. PMID: 37919419, PMCID: PMC10630139, DOI: 10.1038/s41592-023-02040-5.Peer-Reviewed Original Research
2022
Clinical predictors of longer survival in patients with BRAFV600-mutated metastatic melanoma receiving immunotherapy prior to BRAF/MEK inhibition in the metastatic setting.
Kahn A, Perry C, Etts K, Kluger H, Sznol M. Clinical predictors of longer survival in patients with BRAFV600-mutated metastatic melanoma receiving immunotherapy prior to BRAF/MEK inhibition in the metastatic setting. Journal Of Clinical Oncology 2022, 40: 9555-9555. DOI: 10.1200/jco.2022.40.16_suppl.9555.Peer-Reviewed Original ResearchBRAF/MEKiFirst-line immunotherapyBRAF/MEK inhibitionBRAF V600Metastatic melanomaLonger survivalAdverse eventsMedian durationMost patientsBone metastasesClinical predictorsDisease progressionMEK inhibitionAdvanced BRAF V600ECOG PS 0Median ECOG PSFirst-line settingKaplan-Meier methodMost common sitePredictors of survivalECOG PSMedian LDHData cutoffMetastatic settingMedian survival
2021
A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1
Weiss SA, Djureinovic D, Jessel S, Krykbaeva I, Zhang L, Jilaveanu L, Ralabate A, Johnson B, Levit NS, Anderson G, Zelterman D, Wei W, Mahajan A, Trifan O, Bosenberg M, Kaech SM, Perry CJ, Damsky W, Gettinger S, Sznol M, Hurwitz M, Kluger HM. A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1. Clinical Cancer Research 2021, 27: 4757-4767. PMID: 34140403, PMCID: PMC9236708, DOI: 10.1158/1078-0432.ccr-21-0903.Peer-Reviewed Original ResearchConceptsAnti-PD-1/PD-L1Non-small cell lung cancerCell lung cancerRenal cell carcinomaPD-L1Lung cancerDisease progressionCommon treatment-related adverse eventsPD-1/PD-L1 inhibitorsTreatment-related adverse eventsPhase 2 doseSubstantial clinical challengeUnconfirmed partial responseDose-limiting toxicityPD-L1 inhibitorsPhase I trialDose-escalation designPro-inflammatory cytokinesMultiple tumor typesAsymptomatic elevationStable diseaseIntolerable toxicityAdverse eventsMedian durationPartial response
2019
LB1122 Myeloid targeting in combination with PD1 inhibition boosts anti-tumor immunity in melanoma
Krykbaeva I, Damsky W, Turner N, Perry C, Kluger H, Bosenberg M. LB1122 Myeloid targeting in combination with PD1 inhibition boosts anti-tumor immunity in melanoma. Journal Of Investigative Dermatology 2019, 139: b19. DOI: 10.1016/j.jid.2019.06.089.Peer-Reviewed Original ResearchTumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumors
Ayeni D, Miller B, Kuhlmann A, Ho PC, Robles-Oteiza C, Gaefele M, Levy S, de Miguel FJ, Perry C, Guan T, Krystal G, Lockwood W, Zelterman D, Homer R, Liu Z, Kaech S, Politi K. Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumors. Journal For ImmunoTherapy Of Cancer 2019, 7: 172. PMID: 31291990, PMCID: PMC6617639, DOI: 10.1186/s40425-019-0643-8.Peer-Reviewed Original ResearchConceptsTyrosine kinase inhibitorsEGFR-mutant lung cancerMutant lung cancerTumor regressionErlotinib treatmentLung cancerImmune cellsLung tumorsMouse modelEffects of TKIsGrowth factor receptor tyrosine kinase inhibitorsTumor-infiltrating immune cellsDrug resistanceReceptor tyrosine kinase inhibitorsInflammatory immune cellsInflammatory T cellsEffect of erlotinibEGFR mutant lung tumorsInflammatory cellsImmunological profileT cellsCD40 agonistsImmunostimulatory effectsAlveolar macrophagesErlotinibB cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors
Damsky W, Jilaveanu L, Turner N, Perry C, Zito C, Tomayko M, Leventhal J, Herold K, Meffre E, Bosenberg M, Kluger HM. B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors. Journal For ImmunoTherapy Of Cancer 2019, 7: 153. PMID: 31200747, PMCID: PMC6567557, DOI: 10.1186/s40425-019-0613-1.Peer-Reviewed Original ResearchConceptsPD-1 inhibitorsB cell contentB-cell depletionAnti-tumor activityB cellsMuMT miceCell depletionAnti-PD-1 inhibitorsAnti-PD-1 responseB-cell depleting drugsTumor-infiltrating B cellsImpaired B-cell functionT cell-dependent tumor rejectionPD-1 inhibitionMC38 colon cancerB cell functionAnti-tumor effectsB-cell malignanciesMurine cancer modelsCell contentOverall survivalTumor rejectionCD20 antibodyAutoimmune disordersTumor shrinkage
2018
Uncoupling Hepatic Oxidative Phosphorylation Reduces Tumor Growth in Two Murine Models of Colon Cancer
Wang Y, Nasiri AR, Damsky WE, Perry CJ, Zhang XM, Rabin-Court A, Pollak MN, Shulman GI, Perry RJ. Uncoupling Hepatic Oxidative Phosphorylation Reduces Tumor Growth in Two Murine Models of Colon Cancer. Cell Reports 2018, 24: 47-55. PMID: 29972790, PMCID: PMC6056247, DOI: 10.1016/j.celrep.2018.06.008.Peer-Reviewed Original ResearchConceptsControlled-release mitochondrial protonophoreTumor growthGlucose uptakeDiet-induced obesityMurine colon cancer modelColon cancer modelHepatic energy metabolismColon cancer pathogenesisHormonal milieuPlasma insulinFed miceInsulin infusionMurine modelColon cancerCancer modelCancer pathogenesisOxidative phosphorylationNeoplastic growthMitochondrial protonophoreHepatic oxidative phosphorylationObesityUnderlying mechanismEnergy metabolismCancerInsulin
Academic Achievements & Community Involvement
Clinical Care
Overview
Clinical Specialties
Genitourinary Oncology; Medical Oncology
Board Certifications
Medical Oncology
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 2024
Internal Medicine
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 2021
News
News
- June 06, 2025
Yale Cancer Center Researchers and Trainees Present at 2025 ASCO Annual Meeting
- May 14, 2025
Yale Cancer Center Experts Set to Present Advances in Cancer Research at the World’s Largest Clinical Oncology Conference
- December 31, 2024
Accolades, Awards & Honors
- November 02, 2023
Discovering the 'Cytokine Language' That Activates Immune Responses
Get In Touch
Contacts
Appointment Number
Locations
CMCO
Lab
300 George Street, Fl 6
New Haven, CT 06511
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.